Ann: Afamelanotide well tolerated by first stroke patients, page-11

"Being big doesn't always mean being right" Never a truer word has been spoken. Big Pharma not necessarily the best at doing research these days. Smaller more nimble startups with a clear and specialised focus can definitely outperform. eg Clinuvel. Have a look at clinicaltrials.gov if you want another example of this. Overnight an update was posted by the 'big pharma' competition looking to compete with Clinuvel in the EPP space and it appears to me that their Phase III trial is doing an Extension Study. So does that mean another 2 years or more before even finishing Phase III? Wow. The smaller company in Clinuvel already achieved all important FDA approval two years ago. If it's an extra two years that would give Clinuvel time to absolutely dominate market share in the world wide EPP market! Meanwhile CUV moving on with studies in Stroke and DNA repair with their already FDA, EMA, TGA and Israel approved and safe drug.
All IMO DYOR